Department of Pathology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China; Department of Pathology, Yongchuan Hospital Of Chongqing Medical University, Yongchuan 402160, Chongqing, China.
Department of Medical Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China.
Clin Breast Cancer. 2024 Aug;24(6):e429-e451. doi: 10.1016/j.clbc.2024.02.022. Epub 2024 Mar 6.
NUDCD1 (NudC Domain Containing 1) performs an essential function in biological processes such as cell progression, migration, cell cycle, and intracellular material transport. Many solid tumors express it highly, which is a prospective biomarker and therapeutic approach. However, the expression and clinical importance of NUDCD1 across breast cancer is unclear.
The expressions of NUDCD1 in breast cancers and normal breast tissues were studied utilizing the TIMER database and immunohistochemical analysis. Subsequently, we validate the association between the expression of NUDCD1 and clinicopathologic features and prognosis of breast cancer. The immunohistochemical experiments of pathway-related molecules were done on 214 breast cancer tissue microarrays. The investigation of correlation between NUDCD1 expression and tumor immune infiltration was subsequently conducted.
Through the utilization of bioinformatics analysis and immunohistochemical experiments, it was determined that NUDCD1 exhibited upregulation within breast cancer. Furthermore, it was discovered that an elevated expression of NUDCD1 may potentially be linked to a worse prognosis in breast cancer. Our study reveals that the PI3K/AKT/mTOR signaling pathway may perform a function in NUDCD1 regulating breast cancer progression via enrichment analysis. Furthermore, the expression of NUDCD1 may be associated with the degree of immunological infiltration.
The expression of NUDCD1 was explored to be elevated in breast cancer and was observed to be correlated with a poorer prognosis. p-AKT, PI3K, AKT, mTOR, and p-mTOR expression levels underwent significant elevation in breast cancer. The function of NUDCD1 within breast cancer might be associated with the PI3K/AKT/mTOR signaling pathway.
NUDCD1(含 NudC 结构域蛋白 1)在细胞增殖、迁移、细胞周期和细胞内物质运输等生物学过程中发挥着重要作用。许多实体瘤高度表达 NUDCD1,它是一种有前途的生物标志物和治疗方法。然而,NUDCD1 在乳腺癌中的表达和临床意义尚不清楚。
利用 TIMER 数据库和免疫组织化学分析研究了 NUDCD1 在乳腺癌和正常乳腺组织中的表达。随后,我们验证了 NUDCD1 的表达与乳腺癌临床病理特征和预后的关系。在 214 例乳腺癌组织微阵列上进行了与通路相关分子的免疫组织化学实验。随后,对 NUDCD1 表达与肿瘤免疫浸润的相关性进行了研究。
通过生物信息学分析和免疫组织化学实验,确定 NUDCD1 在乳腺癌中上调。此外,发现 NUDCD1 表达水平升高可能与乳腺癌预后不良有关。我们的研究表明,PI3K/AKT/mTOR 信号通路可能通过富集分析在 NUDCD1 调节乳腺癌进展中发挥作用。此外,NUDCD1 的表达可能与免疫浸润程度有关。
NUDCD1 在乳腺癌中的表达上调,并与预后不良相关。p-AKT、PI3K、AKT、mTOR 和 p-mTOR 在乳腺癌中的表达水平显著升高。NUDCD1 在乳腺癌中的功能可能与 PI3K/AKT/mTOR 信号通路有关。